Merck Manual

Please confirm that you are not located inside the Russian Federation

honeypot link

COVID-19: Pathophysiology

COVID-19 Resources Home Page 
By Matthew E. Levison, MD, Adjunct Professor of Medicine, Drexel University College of Medicine

2/15/2021

 

SARS-CoV-2 Host Cell Receptor

 

The surface of SARS-CoV-2 virus is covered by a large number of spike proteins, which are essential for the virus to gain entry into host cells. Each spike protein consists of two subunits, S1 and S2. The S1 subunit at the tip of the spike contains the receptor-binding domain (RBD) that binds to angiotensin-converting enzyme 2 (ACE2), the host cell receptor, while the S2 subunit, located on the stalk of the spike, mediates virus-host cell membrane fusion that is necessary for viral entry (1). For membrane fusion to occur, the S1 and S2 subunits must be cleaved open by transmembrane protease serine 2 (TMPRSS2—1).

ACE2, first identified in 2000, is an enzyme attached to the surface of host cells and is the entry point for SARS-CoV-2. ACE2 is widely distributed throughout the body, being abundantly expressed on nasal epithelial cells, lung alveolar epithelial cells, and small intestinal enterocytes. ACE2 is also expressed in endothelium of vascular beds in organs throughout the body and in arterial smooth muscle cells in many organs studied. In the kidneys, ACE2 is expressed in the apical brush borders of the proximal tubules, as well as glomerular podocytes; but not in endothelial cells (2). The wide distribution of ACE2 receptors throughout the body likely explains the multiorgan effects in COVID-19.

 

ACE2 regulates the renin-angiotensin system by catalyzing the hydrolysis of the octapeptide angiotensin II (AngII, a vasoconstrictor) to the heptapeptide angiotensin 1–7 (Ang1-7, a vasodilator). Ang 1-7 also opposes Ang II’s stimulation of the production of proinflammatory cytokines, such as IL-6. ACE2 has been shown to exhibit a protective function in the lung, cardiovascular system, and other organs, and has been evaluated in clinical trials for the treatment of acute respiratory distress syndrome. The consequent depletion of ACE2 following host cell infection leaves Ang II’s pro-inflammatory stimulation and consequent injury to the lung and other organs unopposed (3).

 

Viral infection of the endothelium results in endothelial cell injury, triggering release of proinflammatory cytokines and microcirculatory dysfunction in the lungs, heart, and liver. One consequence is believed to be a hypercoagulable state that results in microvascular thrombosis. When occurring in the lungs, microvascular thrombosis can impair oxygen exchange; when occurring in veins, it can lead to deep venous thrombosis and pulmonary embolism, and in arteries, ischemic stroke, limb ischemia, and myocardial infarction (4). Excessive bleeding may occur in patients with COVID-19 but is much less common than clotting problems.

 

Genetic variants in the binding site for the SARS-CoV-2 spike-protein and variation in the level of expression and expression pattern of ACE2 in different tissues may provide a genetic basis for differences in host susceptibility, symptoms, and outcome of SARS-CoV-2 infection (5, 6). Also, ACE2 expression has to been found to vary by age; in a study involving patients with asthma, expression of ACE2 by nasal epithelium was found to be less in younger children (4 to 9 years old) than in older children and in people aged 10 to 60 years, and ACE2 expression, after adjusting for sex and asthma, was higher with each subsequent age group, ie, older children (10 to 17 years old), young adults (18 to 24 years old), and adults ≥ 25 years old (7). The lower ACE2 expression in young children relative to adults may help explain why COVID-19 is less prevalent and clinical manifestations are less severe in young children (8), and their frequency of transmission is less (9).

 

 

References

 

1. Huang Y Yang C, Xu X-F, et al: Structural and functional properties of SARS-CoV-2 spike protein: potential antiviral drug development for COVID-19. Acta Pharmacologica Sinica 41: 1141-1149, 2020. doi10.1038/s41401-020-0485-4 https://www.nature.com/articles/s41401-020-0485-4

2. Su H, Yang M, Wan C, et al: Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney International 98(1):P219-227, 2020. https://www.kidney-international.org/article/S0085-2538(20)30369-0/fulltext

3. Liu M, Shi P, Sumners C: Direct anti-inflammatory effects of angiotensin-(1-7) on microglia. Journal of Neurochemistry 136:163-171, 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688174/

4. Lowenstein CJ, Solomon SD: Severe COVID-19 is a microvascular disease. Circulation 142: 1609-1611, 2020. doi: 10.1161/CIRCULATIONAHA.120.050354 https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.120.050354

5. Stawiski E, Diwanji D, Suryamohan K, et al: Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility. [PREPRINT] bioRxiv April 10, 2020 https://www.biorxiv.org/content/10.1101/2020.04.07.024752v1

6. Cao Y, Li L, Feng Z, et al: Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discovery 6, 11, 2020. February 24, 2020. https://www.nature.com/articles/s41421-020-0147-1

7. Bunyavanich S, Do A, Vicencio A: Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA 323(23):2427–2429, 2020. doi:10.1001/jama.2020.8707https://jamanetwork.com/journals/jama/fullarticle/2766524

8. Dong Y, Mo X, Hu Y, et al: Epidemiology of COVID-19 among children in China. Pediatrics 145 (6): e20200702, 2020. https://pediatrics.aappublications.org/content/145/6/e20200702

9. Park YJ, Choe YJ, Park O, et al: Contact tracing during coronavirus disease outbreak, South Korea 2020. Emerging Infectious Diseases October 2020 [early release] July 16, 2020. Accessed July 23, 2020. https://wwwnc.cdc.gov/eid/article/26/10/20-1315-t2

 

 

COVID-19 Resources Home Page